ENDRA Life Sciences Book Value 2011-2026 | NDRA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value ENDRA Life Sciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
2.56 M	5.66 M	7.2 M	10.8 M	7.17 M	4.76 M	6.25 M	5.28 M	-894 K	250 K	605 K	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
10.8 M	-894 K	4.51 M

Quarterly Book Value ENDRA Life Sciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
171 K	1.47 M	1.75 M	2.56 M	-	8.99 M	3.7 M	5.66 M	5.2 M	6.93 M	4.5 M	7.2 M	10.2 M	13.3 M	9.07 M	10.8 M	13.2 M	15 M	17.9 M	7.17 M	3.33 M	7.17 M	7.17 M	4.76 M	4.76 M	4.76 M	4.76 M	6.25 M	6.25 M	6.25 M	6.25 M	5.28 M	5.28 M	5.28 M	5.28 M	-894 K	-894 K	-894 K	-894 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
17.9 M	-894 K	5.89 M

Book Value of other stocks in the Diagnostics research industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Anixa Biosciences ANIX	14 M	$ 2.85	-3.72 %	$ 92.5 K	USA
Centogene N.V. CNTG	77.2 M	-	-6.23 %	$ 30.6 M	Germany
Agilent Technologies A	5.39 B	$ 118.6	0.4 %	$ 36.1 B	USA
Aspira Women's Health AWH	6.73 M	-	-6.19 %	$ 10.5 M	USA
Celcuity CELC	116 M	$ 107.62	-0.63 %	$ 4.25 B	USA
Fulgent Genetics FLGT	1.13 B	$ 13.82	-2.68 %	$ 418 M	USA
Akumin AKU	141 M	-	-17.87 %	$ 25.9 M	Canada
Castle Biosciences CSTL	456 M	$ 27.55	-1.59 %	$ 765 M	USA
Oxford Immunotec Global PLC OXFD	16.7 M	-	-	$ 562 M	Britain
Heska Corporation HSKA	422 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	5.39 M	-	-20.0 %	$ 1.06 M	USA
Charles River Laboratories International CRL	3.21 B	$ 175.77	-1.61 %	$ 8.71 B	USA
ICON Public Limited Company ICLR	9.52 B	$ 108.44	0.16 %	$ 8.94 B	Irlanda
IDEXX Laboratories IDXX	1.61 B	$ 635.29	-0.22 %	$ 51.1 B	USA
Accelerate Diagnostics AXDX	-22.3 M	-	-61.36 %	$ 2.46 M	USA
Global Cord Blood Corporation CO	4.88 B	-	-	$ 399 M	China
Laboratory Corporation of America Holdings LH	8.64 B	$ 283.19	-1.07 %	$ 23.6 B	USA
Fluidigm Corporation FLDM	132 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	16.4 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	548 M	-	0.12 %	$ 80.1 M	China
Lantheus Holdings LNTH	1.09 B	$ 79.15	3.74 %	$ 5.34 B	USA
PRA Health Sciences, Inc. PRAH	1.32 B	-	-	$ 10.7 B	USA
Motus GI Holdings MOTS	2.69 M	-	-34.28 %	$ 263 K	Israel
Mettler-Toledo International MTD	-23.6 M	$ 1 315.61	-0.56 %	$ 27.1 B	Schweiz
Biodesix BDSX	20.9 M	$ 15.5	-1.59 %	$ 2.01 B	USA
Myriad Genetics MYGN	368 M	$ 5.26	4.89 %	$ 487 M	USA
NeoGenomics NEO	837 M	$ 9.53	0.26 %	$ 1.22 B	USA
Biocept BIOC	8.86 M	-	-13.05 %	$ 7.29 M	USA
National Research Corporation NRC	49 M	$ 13.37	-3.47 %	$ 328 M	USA
Natera NTRA	706 M	$ 206.39	3.11 %	$ 20.3 B	USA
Invitae Corporation NVTA	102 M	-	-	$ 21.2 M	USA
BioNano Genomics BNGO	35.4 M	$ 1.12	-1.78 %	$ 1.42 M	USA
Quest Diagnostics Incorporated DGX	16.2 B	$ 208.28	-0.95 %	$ 23.1 B	USA
Danaher Corporation DHR	83.5 B	$ 204.04	-0.9 %	$ 145 B	USA
Organovo Holdings ONVO	10.5 M	-	-2.3 %	$ 19.4 M	USA
OPKO Health OPK	1.37 B	$ 1.22	-2.02 %	$ 847 M	USA
Pacific Biosciences of California PACB	5.35 M	$ 1.51	-7.1 %	$ 453 M	USA
Exact Sciences Corporation EXAS	2.4 B	$ 103.38	0.02 %	$ 19.5 B	USA
Bioventus BVS	221 M	$ 8.8	0.34 %	$ 551 M	USA
DarioHealth Corp. DRIO	96.4 M	$ 10.3	-4.19 %	$ 292 M	Israel
DexCom DXCM	2.75 B	$ 73.0	-1.06 %	$ 28.5 B	USA
PerkinElmer PKI	7.25 B	-	-0.91 %	$ 14.7 B	USA
Psychemedics Corporation PMD	6.67 M	-	-1.84 %	$ 15.3 M	USA
Precipio PRPO	14.4 M	$ 24.78	0.38 %	$ 32.2 M	USA
QIAGEN N.V. QGEN	6.15 B	-	-	$ 10.6 B	Niderland
Quotient Limited QTNT	-35.6 M	-	-11.32 %	$ 1.1 M	Schweiz
Burning Rock Biotech Limited BNR	1.85 B	$ 24.01	-4.59 %	$ 254 M	China
Illumina ILMN	6.3 B	$ 129.9	-2.25 %	$ 20.7 B	USA
Renalytix AI plc RNLX	-7.85 M	-	5.66 %	$ 22.7 M	Britain
VolitionRx Limited VNRX	-26.1 M	$ 0.2	-0.74 %	$ 19.2 M	Singapore